RemeGen Valuation

Q: What is the Fair Price of 9995 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

9995 (HK$14.26) is trading below our estimate of [[fair value]] (HK$71.68)

Is 9995 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9995 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9995 (HK$14.26) is trading below our estimate of fair value (HK$71.68)

Significantly Below Fair Value: 9995 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9995?

Key metric: As 9995 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 9995. This is calculated by dividing 9995's market cap by their current revenue.
What is 9995's PS Ratio?
PS Ratio	4.7x
Sales	CN¥1.52b
Market Cap	CN¥13.40b

9995 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.9x
Enterprise Value/EBITDA	-11.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 9995's PS Ratio compare to its peers?

The above table shows the PS ratio for 9995 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.2x
1530 3SBio	1.6x	9.6%	HK$14.0b
6826 Shanghai Haohai Biological Technology	2.1x	11.8%	HK$13.6b
9969 InnoCare Pharma	11.2x	26.0%	HK$12.5b
6660 AIM Vaccine	5.9x	n/a	HK$7.4b
9995 RemeGen	4.7x	26.1%	HK$14.2b

Price-To-Sales vs Peers: 9995 is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does 9995's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
1530 3SBio	1.6x	9.6%	US$1.80b
6826 Shanghai Haohai Biological Technology	2.1x	11.8%	US$1.75b
2696 Shanghai Henlius Biotech	2.2x	9.7%	US$1.67b
775 CK Life Sciences Int'l. (Holdings)	0.7x	n/a	US$507.59m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 9995 is good value based on its Price-To-Sales Ratio (4.7x) compared to the Hong Kong Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is 9995's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9995 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.7x
Fair PS Ratio	7x

Price-To-Sales vs Fair Ratio: 9995 is good value based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9995 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	HK$14.26	HK$24.97 +75.1%	33.8%	HK$49.39	HK$15.84	n/a	15
Dec ’25	HK$17.76	HK$25.01 +40.8%	31.8%	HK$48.66	HK$15.97	n/a	16
Nov ’25	HK$19.30	HK$25.62 +32.7%	32.5%	HK$49.44	HK$16.02	n/a	15
Oct ’25	HK$17.10	HK$25.18 +47.3%	36.6%	HK$50.12	HK$15.39	n/a	14
Sep ’25	HK$12.46	HK$24.97 +100.4%	36.5%	HK$49.57	HK$15.22	n/a	14
Aug ’25	HK$14.30	HK$37.85 +164.7%	30.1%	HK$63.00	HK$21.00	n/a	14
Jul ’25	HK$24.50	HK$39.94 +63.0%	25.2%	HK$63.00	HK$27.92	n/a	13
Jun ’25	HK$25.35	HK$41.86 +65.1%	26.9%	HK$62.96	HK$27.93	n/a	14
May ’25	HK$27.95	HK$42.88 +53.4%	25.8%	HK$62.99	HK$27.94	n/a	13
Apr ’25	HK$27.15	HK$44.74 +64.8%	29.1%	HK$62.99	HK$25.88	n/a	12
Mar ’25	HK$22.35	HK$53.28 +138.4%	24.9%	HK$66.42	HK$26.01	n/a	13
Feb ’25	HK$17.04	HK$55.48 +225.6%	19.5%	HK$66.76	HK$27.16	n/a	13
Jan ’25	HK$37.45	HK$57.51 +53.6%	13.0%	HK$66.99	HK$38.46	n/a	13
Dec ’24	HK$45.15	HK$57.51 +27.4%	13.0%	HK$66.99	HK$38.46	HK$17.76	13
Nov ’24	HK$44.55	HK$55.79 +25.2%	12.8%	HK$65.27	HK$37.48	HK$19.30	14
Oct ’24	HK$40.30	HK$56.31 +39.7%	15.8%	HK$68.03	HK$36.20	HK$17.10	15
Sep ’24	HK$36.60	HK$58.51 +59.9%	9.3%	HK$67.04	HK$48.49	HK$12.46	14
Aug ’24	HK$45.30	HK$61.22 +35.1%	9.7%	HK$68.72	HK$48.92	HK$14.30	13
Jul ’24	HK$34.25	HK$62.01 +81.1%	11.3%	HK$74.88	HK$48.77	HK$24.50	13
Jun ’24	HK$32.10	HK$63.41 +97.5%	11.3%	HK$76.71	HK$49.97	HK$25.35	13
May ’24	HK$45.80	HK$64.87 +41.6%	11.9%	HK$79.84	HK$50.00	HK$27.95	13
Apr ’24	HK$41.85	HK$68.25 +63.1%	7.4%	HK$80.35	HK$60.51	HK$27.15	12
Mar ’24	HK$54.45	HK$73.97 +35.8%	8.7%	HK$86.53	HK$64.00	HK$22.35	12
Feb ’24	HK$66.45	HK$72.79 +9.5%	9.3%	HK$87.90	HK$64.74	HK$17.04	12
Jan ’24	HK$57.90	HK$70.36 +21.5%	9.5%	HK$83.96	HK$61.84	HK$37.45	13
Dec ’23	HK$47.95	HK$70.90 +47.9%	9.5%	HK$84.08	HK$61.92	HK$45.15	12

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 17:04
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RemeGen Co., Ltd. is covered by 35 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sharon Shi	BOCI Research Ltd.
Wai Chak Yuen	BOCI Research Ltd.
Shun Kei Law	CCB International Securities Limited